Ascendis Pharma A/S (ASND) Earnings Date, Estimates & Call Transcripts $132.68 -0.83 (-0.62%) (As of 11:30 AM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Ascendis Pharma A/S Latest Earnings SummaryLatest Q2 2024 Earnings DateSep. 3ConfirmedActual EPS (Sep. 3) -$2.05 Missed By -$0.51 Consensus EPS (Sep. 3) -$1.54 Ascendis Pharma A/S announced Q2 2024 earnings on September 3, 2024, reporting an EPS of -$2.05, which missed analysts' consensus estimates of -$1.54 by $0.51. Quarterly revenue was reported to be $38.75 million, below the consensus estimate of $94.74 million. With a trailing EPS of -$8.08, Ascendis Pharma A/S's earnings are expected to grow next year, from ($7.45) to ($4.30) per share. Get Ascendis Pharma A/S Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ascendis Pharma A/S and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataASND Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ASND Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Ascendis Pharma A/S Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$2.16-$2.16-$2.16Q2 20242-$1.98-$1.07-$1.53Q3 20242-$1.98-$1.96-$1.97Q4 20242-$1.72-$1.71-$1.72FY 20247-$7.84-$6.90-$7.37Q1 20252-$1.86-$1.56-$1.71Q2 20252-$1.37-$1.25-$1.31Q3 20252-$1.11-$1.01-$1.06Q4 20252-$0.77$1.25$0.24FY 20258($5.11)($2.57)($3.84) Ascendis Pharma A/S Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails9/3/2024Q2 2024-$1.54-$2.05 -$0.51-$2.05$94.74M$38.75M5/2/2024Q1 2024-$1.57-$2.48 -$0.91-$2.48$85.72M$103.11M2/7/2024Q4 2023-$2.15-$1.66+$0.49-$1.66$97.02M$148.62M11/7/2023Q3 2023-$2.63-$3.12 -$0.49-$3.12$52.54M$52.02M9/5/2023Q2 2023-$2.68-$2.35+$0.33-$2.35$41.73M$51.59M4/27/2023Q1 2023-$2.84-$2.12+$0.72-$2.12$24.53M$36.04M Get the Latest News and Ratings for ASND and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. 2/16/2023Q4 2022-$2.50-$3.78 -$1.28-$3.78$20.31M$23.38M Ascendis Pharma A/S Earnings - Frequently Asked Questions When did Ascendis Pharma A/S announce their last quarterly earnings? Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earning data on Tuesday, September 3, 2024. Learn more on ASND's earnings history. Did Ascendis Pharma A/S beat their earnings estimates last quarter? In the previous quarter, Ascendis Pharma A/S (NASDAQ:ASND) missed the analysts' consensus estimate of ($1.54) by $0.51 with a reported earnings per share (EPS) of ($2.05). Learn more on analysts' earnings estimate vs. ASND's actual earnings. How much revenue does Ascendis Pharma A/S generate each year? Ascendis Pharma A/S (NASDAQ:ASND) has a recorded annual revenue of $288.08 million. How much profit does Ascendis Pharma A/S generate each year? Ascendis Pharma A/S (NASDAQ:ASND) has a recorded net income of -$521.07 million. ASND has generated -$8.08 earnings per share over the last four quarters. What is Ascendis Pharma A/S's EPS forecast for next year? Ascendis Pharma A/S's earnings are expected to grow from ($7.45) per share to ($4.30) per share in the next year. More Earnings Resources from MarketBeat Related Companies BNTX Earnings Date BGNE Earnings Date TEVA Earnings Date MRNA Earnings Date VTRS Earnings Date GMAB Earnings Date SMMT Earnings Date SRPT Earnings Date RDY Earnings Date PCVX Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! This page (NASDAQ:ASND) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.